Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients
IntroductionBreast cancer is a highly heterogeneous malignancy, characterized by an intricate, hypersialylated tumor microenvironment that actively inhibits immune functions. Although immune checkpoint inhibitors have marked clinical advantages in various tumor types, their efficacy in Triple-Negati...
Saved in:
| Main Authors: | Hamza Benthami, Basma Zohair, Ibtissam Rezouki, Oumayma Naji, Kenza Miyara, Simohamed Ennachit, Mohamed Elkarroumi, Hind Aschawa, Abdallah Badou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573365/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phosphoproteomics identifies microglial Siglec‐F inflammatory response during neurodegeneration
by: Nader Morshed, et al.
Published: (2020-12-01) -
Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec‐7 and Siglec‐9
by: Avijit K. Adak, et al.
Published: (2025-01-01) -
Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer
by: Ibtissam Rezouki, et al.
Published: (2025-08-01) -
Siglecs-mediated immune regulation in neurological disorders
by: Huifang Tu, et al.
Published: (2024-12-01) -
Insights into Siglec‐7 Binding to Gangliosides: NMR Protein Assignment and the Impact of Ligand Flexibility
by: Cristina Di Carluccio, et al.
Published: (2025-06-01)